Instrumento Inactivo

Acciones Avanir Pharmaceuticals Inc

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Avanir Pharmaceuticals : Announces Appointment of Rohan Palekar as President and Chief Executive Officer	20/01/16
Avanir Pharmaceuticals : Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease	10/12/15
Avanir Pharmaceuticals : Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease	22/09/15
Avanir Pharmaceuticals : Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026	11/08/15
Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference	23/07/15

Directores	Puesto	Edad	Desde
Dan Dalton CMP	Compliance Officer	-	01/06/16
Kelly Parker IRO	Public Communications Contact	-	01/06/15
Aneta Ferguson LAW	General Counsel	-	01/01/15

Administradores	Puesto	Edad	Desde
Donald Hayden CHM	Chairman	68	-
Robert McQuade BRD	Director/Board Member	67	-
Thomas DesRosier BRD	Director/Board Member	69	-

Sector

	Varia. 1 de ene.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 mil M
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 mil M
ARGENX SE	+1,69 %	22,15 mil M
BIONTECH SE	-17,37 %	21,02 mil M
GENMAB A/S	-9,30 %	18,15 mil M
WUXI APPTEC CO., LTD.	-41,01 %	16,74 mil M
BEIGENE, LTD.	-14,85 %	16,05 mil M
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 mil M
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 mil M